NASDAQ:ANGO AngioDynamics (ANGO) Stock Price, News & Analysis $12.46 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$12.30 -0.16 (-1.28%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About AngioDynamics Stock (NASDAQ:ANGO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AngioDynamics alerts:Sign Up Key Stats Today's Range$12.43▼$13.5050-Day Range$6.83▼$12.9452-Week Range$5.26▼$13.50Volume1.55 million shsAverage Volume1.08 million shsMarket Capitalization$504.26 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingBuy Company OverviewAngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.Read More… AngioDynamics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks81st Percentile Overall ScoreANGO MarketRank™: AngioDynamics scored higher than 81% of companies evaluated by MarketBeat, and ranked 235th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingAngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAngioDynamics has only been the subject of 1 research reports in the past 90 days.Read more about AngioDynamics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AngioDynamics are expected to grow in the coming year, from ($0.37) to ($0.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AngioDynamics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AngioDynamics is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAngioDynamics has a P/B Ratio of 2.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AngioDynamics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.03% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 6.70%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAngioDynamics does not currently pay a dividend.Dividend GrowthAngioDynamics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-0.99 Percentage of Shares Shorted2.03% of the outstanding shares of AngioDynamics have been sold short.Short Interest Ratio / Days to CoverAngioDynamics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in AngioDynamics has recently decreased by 6.70%, indicating that investor sentiment is improving significantly. News and Social Media4.1 / 5News Sentiment1.41 News SentimentAngioDynamics has a news sentiment score of 1.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for AngioDynamics this week, compared to 3 articles on an average week.Search Interest9 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, AngioDynamics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $49,979.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of AngioDynamics is held by insiders.Percentage Held by Institutions89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AngioDynamics' insider trading history. Receive ANGO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter. Email Address ANGO Stock News HeadlinesInsider Selling: AngioDynamics, Inc. (NASDAQ:ANGO) SVP Sells 4,060 Shares of StockJanuary 18, 2025 | insidertrades.comAngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb IschemiaJanuary 30 at 8:04 AM | businesswire.comPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader in the country – in the next 30 days. In fact, I believe it could begin as soon as March 13th… Meaning you don’t have much time to prepare.January 30, 2025 | Timothy Sykes (Ad)With 74% institutional ownership, AngioDynamics, Inc. (NASDAQ:ANGO) is a favorite amongst the big gunsJanuary 25, 2025 | finance.yahoo.comAngioDynamics Highlights Strategic Growth at Healthcare ConferenceJanuary 16, 2025 | tipranks.comAngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The SharesJanuary 16, 2025 | seekingalpha.comAngioDynamics Publishes APEX-AV Trial Results In JSCAIJanuary 14, 2025 | markets.businessinsider.comAngioDynamics announces publication of APEX-AV trial results in JSCAIJanuary 13, 2025 | markets.businessinsider.comSee More Headlines ANGO Stock Analysis - Frequently Asked Questions How have ANGO shares performed this year? AngioDynamics' stock was trading at $9.16 at the start of the year. Since then, ANGO shares have increased by 36.0% and is now trading at $12.46. View the best growth stocks for 2025 here. How were AngioDynamics' earnings last quarter? AngioDynamics, Inc. (NASDAQ:ANGO) posted its earnings results on Wednesday, January, 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.07. The firm's revenue was down .1% compared to the same quarter last year. Does AngioDynamics have any subsidiaries? The following companies are subsidiaries of AngioDynamics: Eximo Medical Ltd., RadiaDyne LLC, Clinical Devices, Vortex Medical, Navilyst Medical Inc., FlowMedica, Oncovionic, and more. Who are AngioDynamics' major shareholders? AngioDynamics' top institutional investors include Assenagon Asset Management S.A. (0.67%), White Pine Capital LLC (0.16%), Rhumbline Advisers (0.15%) and Moody National Bank Trust Division (0.14%). Insiders that own company stock include James C Clemmer, James C Clemmer, Stephen A Trowbridge, Wesley Johnson, Warren Nighan Jr and Dave Helsel. View institutional ownership trends. How do I buy shares of AngioDynamics? Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AngioDynamics own? Based on aggregate information from My MarketBeat watchlists, some other companies that AngioDynamics investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), Voyager Therapeutics (VYGR), The RMR Group (RMR), AUO (AUOTY) and DiamondRock Hospitality (DRH). Company Calendar Last Earnings1/08/2025Today1/30/2025Next Earnings (Estimated)4/03/2025Fiscal Year End5/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:ANGO CUSIP03475V10 CIK1275187 Webwww.angiodynamics.com Phone(518) 795-1400Fax518-795-1401Employees760Year Founded1988Price Target and Rating Average Stock Price Target$13.00 High Stock Price Target$15.00 Low Stock Price Target$12.00 Potential Upside/Downside+1.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($5.63) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-184,350,000.00 Net Margins-79.38% Pretax Margin-82.86% Return on Equity-7.26% Return on Assets-4.78% Debt Debt-to-Equity RatioN/A Current Ratio1.98 Quick Ratio1.24 Sales & Book Value Annual Sales$303.91 million Price / Sales1.71 Cash Flow$4.56 per share Price / Cash Flow2.81 Book Value$4.62 per share Price / Book2.77Miscellaneous Outstanding Shares40,470,000Free Float38,281,000Market Cap$518.22 million OptionableOptionable Beta0.59 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for February 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NASDAQ:ANGO) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredDonald Trump is about to free crypto from its chains …On October 25th, Juan said Bitcoin would cross $100,000 before the inauguration. Now he thinks it could rea...Weiss Ratings | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AngioDynamics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AngioDynamics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.